In a prostate cancer model, castration-resistant prostate cancer (CRPC) cells transformed into NE-like cancer upon repeated enzalutamide treatment exhibited increased DNA accessibility at the CRBN promoter region—comparable to that observed in the H660 NEPC cell line. This evidence concerns the gene CRBN and prostate carcinoma.